Keros Therapeutics (NASDAQ:KROS) Cut to “Hold” at TD Cowen

Keros Therapeutics (NASDAQ:KROS) was downgraded by equities researchers at TD Cowen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports.

KROS has been the topic of a number of other research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a research note on Thursday, November 7th. Guggenheim reaffirmed a “buy” rating and set a $102.00 target price (up previously from $96.00) on shares of Keros Therapeutics in a report on Wednesday, December 4th. Wells Fargo & Company boosted their price target on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Scotiabank assumed coverage on Keros Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $85.67.

Keros Therapeutics Stock Up 2.2 %

Shares of NASDAQ KROS opened at $18.83 on Thursday. Keros Therapeutics has a fifty-two week low of $15.67 and a fifty-two week high of $73.00. The business has a 50 day moving average price of $59.11 and a two-hundred day moving average price of $52.63. The firm has a market cap of $762.75 million, a PE ratio of -3.61 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company’s quarterly revenue was up 4750.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.33) earnings per share. On average, analysts anticipate that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in KROS. FMR LLC boosted its stake in Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after purchasing an additional 179,374 shares in the last quarter. Alkeon Capital Management LLC grew its position in Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after buying an additional 298,694 shares during the last quarter. Darwin Global Management Ltd. grew its position in Keros Therapeutics by 6.3% in the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock worth $68,772,000 after buying an additional 89,952 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after buying an additional 577,220 shares in the last quarter. Finally, Holocene Advisors LP lifted its position in shares of Keros Therapeutics by 22.5% during the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock valued at $48,959,000 after acquiring an additional 154,784 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.